The activity of the Complementary Medicine Office from the Research & Development Department of Romvac Company S.A.


Starting with 2016, specific Y-immunoglobulin therapy is recommended within the Imunoinstant Complementary Medicine Office, which is part of the Romvac Company S.A. Research & Development Department.

Currently, the cabinet has a number of over 5000 patients, with a wide range of diseases, including:

  • patients with type I or type II diabetes;

  • patients with palmar-plantar psoriasis with nail involvement;

  • patients with nail psoriasis;

  • patients with generalized psoriasis;

  • patients with bullous epidermolysis;

  • patients with urinary infection caused by Escherichia coli, Klebsiella spp., Proteus mirabilis, Enterococcus faecalis, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus grup B.

  • patients with genital infection caused by Candida spp., Escherichia coli, Enterococcus faecalis, Klebsiella spp., Streptococcus grup B., Staphylococcus , HPV (9 tulpini), Herpes Simplex tip 1 (HSV 1);

  • patients with herpes infection caused by Herpes Simplex (HSV 1);

  • patients with gastric infection caused by Helicobcater pylori;

  • patients with gastrointestinal infection caused by Clostridium difficile, Escherichia coli;

  • patients with periodontists infection caused by Staphylococcus spp., Streptococcus spp.;

  • patients with acne of various forms caused by Staphylococcus aureus;

  • patients with different type of dermatitis caused by infection with Staphylococcus aureus;

  • patients with infected wounds caused by Staphylococcus aureus MRSA, Pseudomonas aeruginosa, Klebsiella spp., Candida spp., Escherichia coli;

  • patients with respiratory infection caused by Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa;